Saudi Food and Drug Authority (SFDA) has announced a cancellation of registrations of four products because two of them are not bioequivalent to the reference product, and the other two products have not been marketed for more than two years. Executive Director of Communication and Awareness Department in SFDA Dr. Abdulrahman Al-Sultan said that drug companies and manufacturers' registration committee in SFDA decided to cancel the registration of Pedovex and Cardlet products, because they are not bioequivalent with the reference product and they will be withdrawn from the markets, in addition to the registration of Vidapart and Clopex products for not marketing them for more than two years. Dr. Al-Sultan pointed out that SFDA asked the products agents to recall the products from the beneficiaries, affirming that the users of the four products should visit a doctor immediately.
